

Effect of Vitamin D supplement use on serum concentrations of total 25OHD levels in elderly women[☆]

P.B. Rapuri*, J.C. Gallagher

Bone Metabolism Unit, School of Medicine, Creighton University, 601 North 30th Street, Room 6718, Omaha, NE 68131, USA

Abstract

Vitamin D₂ and D₃ are generally considered equipotent in humans. As Vitamin D₂ supplements are commonly used by elderly in United States, we determined the contribution of 25OHD₂ to the total serum 25OHD levels by HPLC in elderly women who reported taking Vitamin D₂ supplements ($n = 56$) and also in a group of randomly selected unsupplemented women ($n = 60$). In addition, we compared the total serum 25OHD measured by HPLC with competitive protein-binding assay (CPBA), a method routinely employed to measure Vitamin D status. A correlation of 0.91 ($P < 0.001$) was observed between the two methods for the serum total 25OHD measurement. The mean serum 25OHD level in Vitamin D₂ supplemented group was significantly higher than in unsupplemented group measured by HPLC (32 versus 28 ng/ml) and marginally higher measured by CPBA (33 vs. 31 ng/ml). Seventy eight percent of women taking Vitamin D₂ supplements had appreciable amounts of circulating 25OHD₂, which constituted about 25 percent of their total serum 25OHD. It is also interesting to note that Vitamin D deficiency was less prevalent in elderly women taking Vitamin D₂ supplements (1.8%) compared to women not taking any supplements (12%).

© 2004 Elsevier Ltd. All rights reserved.

Keywords: 25-Hydroxy-vitamin D; 25OHD; HPLC; Vitamin D supplement; Competitive protein-binding assay; 25OHD₂

1. Introduction

Vitamin D exists in two forms, cholecalciferol (Vitamin D₃) synthesized endogenously from 7-dehydrocholesterol in the skin by the action of UV radiation and, plant derived ergocalciferol (Vitamin D₂) formed exogenously by irradiation of ergosterol. Vitamin D supplements use either cholecalciferol or ergocalciferol as their source of Vitamin D. Some of the commonly used vitamin supplements in United States like Centrum, Walgreens, Osco multivitamin etc. use Vitamin D₂ as their source of Vitamin D.

In early 1990's, both Vitamin D₂ and D₃ were considered equipotent. However, later research in different animal species showed differences in response to Vitamin D₂ and D₃ [1–3]. In humans, it was originally thought that both Vitamin D₂ and D₃ follow the same metabolic pathway and are equally bioactive in normal subjects [4,5]. Later studies suggested differential response to Vitamin D₂ and D₃ in humans as well [6–8].

In United States, about 50% of women above the age of 50 years use vitamin and mineral supplements [9]. As some of the Vitamin D supplements commonly used by the elderly have Vitamin D₂ as their source of Vitamin D, in the present study, we estimated the contribution of 25OHD₂ to the total serum 25OHD levels by HPLC in elderly women taking Vitamin D₂ supplements. In addition, in women taking Vitamin D₂ supplements and in a randomly selected group of women not taking any vitamin supplements, we compared the total serum 25OHD levels measured by HPLC with that measured by competitive protein-binding assay (CPBA), a routinely employed method to measure circulating 25OHD levels.

2. Materials and methods

Serum samples were obtained from a study population consisting of 489 elderly women, age range 65–77 years, enrolled in an osteoporosis intervention trial, Sites Testing Osteoporosis Prevention/Intervention Treatment (STOP IT), intended to test the efficacy of three therapies in reversing bone loss in proximal femur and spine compared with placebo. The subjects were ambulatory, free-living, healthy volunteers. The information about the multivitamin supplement use was obtained by a questionnaire administered to

[☆] Presented at the 12th Workshop on Vitamin D (Maastricht, The Netherlands, 6–10 July 2003).

* Corresponding author. Tel.: +1-402-280-4163; fax: +1-402-280-4517.
E-mail address: thiyyari@creighton.edu (P.B. Rapuri).

the subjects by the study personnel. The form of Vitamin D (either D₂ or D₃) used in the supplements was obtained from the package inserts. Of the total of 489 women, 307 were not taking any Vitamin D supplements and 182 were taking a Vitamin D supplement, of which 56 were taking a Vitamin D₂ supplement. Women taking a Vitamin D₂ supplement were taking about 400 IU/day. 25OHD measurements by HPLC and CPBA were done on a total of 116 subjects, a randomly selected group of unsupplemented women ($n = 60$) and in women taking Vitamin D₂ supplements ($n = 56$). The protocol was approved by Creighton University Institutional Review Board.

3. 25OHD measurement

Fasting blood samples were collected from the subjects, allowed to clot, centrifuged at 4 °C for 15 min at 2056 × g to separate serum. The serum was stored frozen at –70 °C until analysis.

The total 25OHD measurement was performed both by CPBA and HPLC after precipitating plasma proteins with acetonitrile.

3.1. Competitive protein-binding assay

Total serum 25OHD was measured by CPBA [10] after extraction and purification of serum on Sep-Pak C-18 and silica cartridges (Waters Associates, Milford, MA) [11]. Briefly, after precipitating plasma proteins using acetonitrile, the supernate was back washed with potassium phosphate, 0.4 M (pH 10.5) to enhance the solubilization of lipids. The samples were then extracted on a reverse phase Sep Pak C18 columns. The acetonitrile fraction containing the Vitamin D metabolites was taken through a normal phase extraction with a silica Sep Pak cartridge, where the 25OHD was eluted with 96:4 hexane: *iso*-propanol. 25OHD was quantitated by CPBA employing normal rat serum as the source of binding protein. The minimum detection limit for the assay was 12.5 nmol/l (5 ng/ml) and the inter-assay variation was 5%.

3.2. HPLC

Total serum 25OHD was estimated by HPLC after pre-purification of the acetonitrile extract of serum by solid phase extraction using “Bond-Elut LRC” C18/OH cartridges and Sep-Pak Silica cartridges (Waters Associates, Milford, MA) [12]. HPLC of the purified extract was performed using a Shimadzu LC-10 system with Shimadzu LC-10AT pump, GT-104 degasser, Sil 10A Injector (autosampler) with sample cooler, CTO-10A column oven and SCL-10A system controller. The separation of 25OHD₂ and 25OHD₃ was achieved on a 0.45 i.d. × 25 cm (5 μm) Zorbax SIL column using hexane/*iso*-propanol (97/3) at a flow rate of 2 ml/min. 25OHD₂ and 25OHD₃ were detected

Table 1
Characteristics of the subjects in unsupplemented and Vitamin D₂ supplemented women

Variable	Unsupplemented	Vitamin D ₂ supplemented
<i>N</i>	60	56
Age (years)	71.8 ± 0.45	71.9 ± 0.42
Height (cm)	159.5 ± 0.82	159 ± 0.89
Weight (kg)	67.7 ± 1.70	66.9 ± 1.67
Dietary calcium intake (mg/day)	735 ± 35.5	806 ± 35 ^a
Dietary Vitamin D intake (IU/day) ^b	148.7 ± 11.5	529.9 ± 9.9 ^a

^a $P < 0.05$ compared to unsupplemented group.

^b Includes dietary and supplemental Vitamin D.

using a Shimadzu SPD-10A UV-Vis detector and the data was analyzed using the CLASS-VP chromatography data system. The total 25OHD was computed by measuring both 25OHD₂ and 25OHD₃. The minimum detection limit for the assay was about 2.5 ng/ml and the inter-assay variation was less than 1%.

4. Statistical analysis

All analyses were done using SPSS for windows (Version 11.0, SPSS, Chicago, IL). The characteristics and serum 25OHD levels between the unsupplemented and Vitamin D₂ supplemented women were compared using Student's *t*-test. Pearson's correlation coefficient and simple linear regression methods were used to assess the relation between the two methods of 25OHD estimation.

5. Results and discussion

The characteristics of the subjects of unsupplemented and Vitamin D₂ supplemented groups are given in Table 1. There were no significant differences between the two groups with respect to age and weight. Dietary calcium intake and Vitamin D intake were significantly higher in Vitamin D₂ supplemented women compared to unsupplemented group (Table 1). The mean serum 25OHD measured by CPBA in Vitamin D₂ group was 33.0 ± 1.6 ng/ml and in the unsupplemented group the levels were 31.2 ± 1.3 ng/ml (Table 2). The

Table 2
Mean serum 25OHD concentrations in unsupplemented and Vitamin D₂ supplemented women

Variable	Unsupplemented	Vitamin D ₂ supplemented
<i>N</i>	60	56
Total 25OHD (CPBA) (ng/ml)	31.2 ± 1.3	33.0 ± 1.6
Total 25OHD (HPLC) (ng/ml)	27.7 ± 1.2	31.6 ± 1.4 ^a
25OHD ₃ (HPLC) (ng/ml)	26.8 ± 1.2	23.2 ± 1.6
25OHD ₂ (HPLC) (ng/ml)	0.9 ± 0.40	8.4 ± 0.80

Values are mean ± S.E.M.

^a $P < 0.05$ compared to unsupplemented group.




Fig. 1. Correlation between competitive binding assay (CPBA) and HPLC methods for serum total 25OHD measurement.

mean serum 25OHD determined by HPLC in women receiving Vitamin D₂ supplement (31.6 ± 1.4 ng/ml) was significantly higher when compared to the mean 25OHD in women not receiving any Vitamin D supplement (27.7 ± 1.21 ng/ml) (Table 2). The 25OHD measurements done by CPBA were not different from that measured by HPLC. The mean concentrations of serum 25OHD observed in the present study agree with previously reported values determined by HPLC or CPBA [13] in normal subjects [14]. We observed a good correlation between CPBA and HPLC for serum 25OHD measurement. The overall correlation between CPBA and HPLC for the total serum 25OHD was about 0.91 ($P < 0.001$) (Fig. 1). Other studies comparing HPLC and CPBA

showed a correlation of 0.89 [15] and 0.94 [16] between HPLC and CPBA for total serum 25OHD measurement, which is similar to our observation. In a recent study conducted to assess the inter-laboratory variation for the measurement of serum 25OHD, Lips et al. [17] reported that the mean serum 25OHD was about 80% higher when measured by CPBA than by HPLC. From our results, it appears that serum 25OHD measured by CPBA with prior chromatography step gives a fairly accurate measurement comparable to HPLC.

In the present study, about 78% of women taking a Vitamin D₂ supplement had appreciable amounts of serum 25OHD₂ (Fig. 2), while subjects not taking any Vitamin




Fig. 2. Serum 25OHD₂, 25OHD₃, and total 25OHD measured by HPLC in women taking Vitamin D₂ supplements.

D supplement had negligible amounts. In women taking Vitamin D₂ supplements, approximately 25% of the total serum 25OHD was contributed by 25OHD₂. About 20% of Vitamin D₂ supplemented women would have been classified as Vitamin D deficient if their serum 25OHD₂ levels were not accounted for the total 25OHD content (Fig. 2).

Vitamin D deficiency is a significant risk factor for bone loss and subsequent fracture. In the present study carried out in Omaha (41° N), Vitamin D deficiency (<15 ng/ml) was less prevalent (1.8%) in Vitamin D₂ supplemented group (Fig. 2). However, in elderly subjects not taking any vitamin supplements, about 12% had serum 25OHD levels below 15 ng/ml. In Boston (42.2° N), it has been reported that in elderly nursing home residents about 40% had serum 25OHD levels below 10 ng/ml and about 80% had below 15 ng/ml in the winter time [18]. Seasonal variation in serum 25OHD levels has also been reported in our study population [19]. Another recent study reported that about 13.6% of the population (age range 18–86 years) attending a Boston outpatient clinic had serum 25OHD levels less than 16 ng/ml in winter time [20]. They also reported that Vitamin D supplementation is a positive determinant of serum 25OHD concentration with about 65% of those taking a Vitamin D supplement having serum 25OHD levels as high as 32 ng/ml.

In conclusion, in women taking Vitamin D₂ supplements about 25% of their serum total 25OHD is contributed by 25OHD₂ and about 20% would have been classified as Vitamin D deficient if their 25OHD₂ levels were not accounted for the total Vitamin D content. Further, though HPLC is advantageous to know the relative contribution of diet/Vitamin D supplement and exposure to UV light to the total 25OHD pool, to assess the general Vitamin D status, CPBA with prior chromatography step gives a fairly accurate Vitamin D status of an individual.

Acknowledgements

This work was supported by National Institute of Health Research grants, UO1-AG10373 and RO1-AG10358. We thank Karen A. Rafferty for her help in food dairy data collection and analysis.

References

- [1] R.L. Horst, J.L. Napoli, E.T. Littledike, Discrimination in the metabolism of orally dosed ergocalciferol and cholecalciferol by the pig, rat and chick, *Biochem. J.* 204 (1982) 185–189.
- [2] R.D. Hunt, F.G. Garcia, R.J. Walsh, A comparison of the toxicity of ergocalciferol and cholecalciferol in rhesus monkeys (*Macaca mulatta*), *J. Nutr.* 102 (1972) 975–986.
- [3] S.J. Marx, G. Jones, R.S. Weinstein, G.P. Chrousos, D.M. Renquist, Differences in mineral metabolism among nonhuman primates receiving diets with only Vitamin D3 or only Vitamin D2, *J. Clin. Endocrinol. Metab.* 69 (1989) 1282–1290.
- [4] M.F. Holick, H.F. DeLuca, Metabolism of Vitamin D, in: D.E.M. Lawson (Ed.), "Vitamin D", Academic Press, 1978.
- [5] A.W. Norman, Vitamin D: The Calcium Homeostatic Steroid Hormone, Academic Press, New York, 1979.
- [6] L. Tjellesen, C. Christiansen, P. Rodbro, L. Hummer, Different metabolism of Vitamin D2 and Vitamin D3 in epileptic patients on carbamazepine, *Acta Neurol. Scand.* 71 (1985) 385–389.
- [7] L. Tjellesen, L. Hummer, C. Christiansen, P. Rodbro, Different metabolism of Vitamin D2/D3 in epileptic patients treated with phenobarbitone/phenytoin, *Bone* 7 (1986) 337–342.
- [8] H.M. Trang, D.E. Cole, L.A. Rubin, A. Pierratos, S. Siu, R. Vieth, Evidence that Vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does Vitamin D2, *Am. J. Clin. Nutr.* 68 (1998) 854–858.
- [9] L.S. Balluz, S.M. Kieszak, R.M. Philen, J. Mulinare, Vitamin and mineral supplement use in the United States: results from the Third National Health and Nutrition Examination Survey, *Arch. Fam. Med.* 9 (2000) 258–262.
- [10] J.G. Haddad, K.J. Chyu, Competitive protein-binding radioassay for 25-hydroxycholecalciferol, *J. Clin. Endocrinol. Metab.* 33 (1971) 992–995.
- [11] T.A. Reinhardt, R.L. Horst, 1988. Simplified assays for the determination of 25-OHD, 24, 25-(OH)2D and 1,25-(OH)2D, in: A.W. Norman, K. Schaefer, H.G. Grigoleit, D.V. Herrath (Eds.), "Vitamin D, Molecular, Cellular, and Clinical Endocrinology", Walter de Gruyter, Berlin, Germany.
- [12] S. Wei, H. Tanaka, T. Kubo, M. Ichikawa, Y. Seino, A multiple assay for Vitamin D metabolites without high-performance liquid chromatography, *Anal. Biochem.* 222 (1994) 359–365.
- [13] J.A. Eisman, A.J. Hamstra, B.E. Kream, H.F. DeLuca, A sensitive, precise, and convenient method for determination of 1,25-dihydroxyvitamin D in human plasma, *Arch. Biochem. Biophys.* 176 (1976) 235–243.
- [14] G. Jones, Assay of vitamins D2 and D3, and 25-hydroxyvitamins D2 and D3 in human plasma by high-performance liquid chromatography, *Clin. Chem.* 24 (1978) 287–298.
- [15] L. Hummer, L. Tjellesen, H. Rickers, C. Christiansen, Measurement of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 in clinical settings, *Scand. J. Clin. Lab Invest.* 44 (1984) 595–601.
- [16] R.L. Norris, M.J. Thomas, P.W. Craswell, Assessment of a two-step high-performance liquid chromatographic assay using dual-wavelength ultraviolet monitoring for 25-hydroxyergocalciferol and 25-hydroxycholecalciferol in human serum or plasma, *J. Chromatogr.* 381 (1986) 53–61.
- [17] P. Lips, M.C. Chapuy, B. Dawson-Hughes, H.A. Pols, M.F. Holick, An international comparison of serum 25-hydroxyvitamin D measurements, *Osteoporos. Int.* 9 (1999) 394–397.
- [18] A.R. Webb, C. Pilbeam, N. Hanafin, M.F. Holick, An evaluation of the relative contributions of exposure to sunlight and of diet to the circulating concentrations of 25-hydroxyvitamin D in an elderly nursing home population in Boston, *Am. J. Clin. Nutr.* 51 (1990) 1075–1081.
- [19] P.B. Rapuri, H.K. Kinyamu, J.C. Gallagher, V. Haynatzka, Seasonal changes in calciotropic hormones, bone markers, and bone mineral density in elderly women, *J. Clin. Endocrinol. Metab.* 87 (2002) 2024–2032.
- [20] L. Margiloff, S.S. Harris, S. Lee, R. Lechan, B. Dawson-Hughes, Vitamin D status of an outpatient clinic population, *Calcif. Tissue Int.* 69 (2001) 263–267.